Quarterly report pursuant to Section 13 or 15(d)

SHARE-BASED COMPENSATION (Tables)

v3.23.2
SHARE-BASED COMPENSATION (Tables)
 6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Schedule of summarizes share-based compensation expense
                               
    Three Months Ended
June 30,		    

Six Months Ended

June 30,

  
    2023     2022     2023     2022  
Research and development   $ 570     $ 1,169     $ 1,101     $ 2,135  
Sales and marketing     517       1,197       1,024       2,279  
General and administrative     904       4,541       1,798       9,015  
Cost of sales     7       65       14       107  
Total share-based compensation   $ 1,998     $ 6,972     $ 3,937     $ 13,536  
Schedule of common stock options
  Number of
Shares		     Weighted
Average
Exercise Price		     Weighted Average Remaining
Contractual
Life (Years)		     Weighted-
Average
Grant Date
Fair Value		  
Outstanding, December 31, 2022     7,812,178     $ 3.70       6.56     $ 2.23  
Forfeited     (31,523 )     2.26       -       1.46  
Expired     (14,421 )     5.40       -       2.86  
Outstanding, June 30, 2023(a)     7,766,234     $ 3.70       6.02     $ 1.98  
Exercisable, June 30, 2023(b)     5,566,087     $ 3.89       5.11     $ 2.06  

 

 
(a) There was no aggregate intrinsic value of all stock options outstanding as of June 30, 2023.
(b) There was no aggregate intrinsic value of all vested/exercisable stock options as of June 30, 2023.
Schedule of unvested restricted stock units
    Number of
RSUs		     Weighted
Average
Grant Date
Fair Value		  
Outstanding (nonvested), December 31, 2022     4,267,746     $ 3.58  
Granted     681,620       0.56  
Released     (387,204 )     5.44  
Forfeited     (51,611 )     3.25  
Outstanding (nonvested), June 30, 2023     4,510,551     $ 2.97